| Bioactivity | GB1908 is a selective and orally active galectin-1 inhibitor with Ki values of 57 nM and 72 nM for human and mouse galectin-1, respectively. GB1908 displays >50-fold selectivity over galectin-3. GB1908 can be used for the study of lung cancer[1]. |
| Invitro | GB1908（0.1-10 μM；16 小时）可抑制 Jurkat 细胞中半乳糖凝集素-1 诱导的细胞凋亡（IC50 为 850 nM）[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> GB1908 相关抗体: Apoptosis Analysis[1] Cell Line: |
| In Vivo | GB1908（化合物 5d；30 mg/kg；口服；每天两次；持续 21 天）在同源小鼠模型中降低了原发性肺癌 LL/2 的生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C18H18Cl2N4O5S2 |
| Molar Mass | 505.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fredrik R Zetterberg, et al. Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung Cancer. J Med Chem. 2024 May 28. |